A Study to Evaluate Safety and Efficacy of L19TNF Plus Lomustine in Patients With Glioblastoma at First Progression

This study evaluates the safety and effectiveness of combining a targeted drug called L19TNF with a chemotherapy drug called lomustine (CCNU) for people with glioblastoma (an aggressive brain tumor) that has come back after initial treatment. **You may be eligible if...** - You are 18 years old or older - You have been diagnosed with glioblastoma that has clearly returned or progressed for the first time - Your tumor is IDH-wildtype (a specific genetic marker) - Your overall health and ability to function are reasonably good (Karnofsky score ≥70%) - You have tested negative for HIV, hepatitis B, and hepatitis C - If you can become pregnant, you are using highly effective contraception **You may NOT be eligible if...** - This is your second or later recurrence of glioblastoma - You have severe other medical conditions - You are pregnant or breastfeeding - You have had prior treatment with lomustine - Your blood counts, liver, or kidney function are outside acceptable ranges Talk to your doctor to see if this trial is right for you.